Lessons from the past--looking to the future. Newborn screening

Area of Science:

• Genetics and genomics
• Public health screening programs
• Neonatal medicine

Background:

• Newborn screening is currently in its early stages of development.
• Advancements in technologies like tandem mass spectrometry (MS/MS) and DNA analysis are expanding screening capabilities.
• The Guthrie specimen is a key resource for both current and future newborn screening initiatives.

Observation:

• DNA analysis of the Guthrie specimen allows for primary screening of numerous disorders previously undetectable at birth.
• Potential new screening targets include type I diabetes, severe combined immunodeficiency, fragile X syndrome, hereditary hemochromatosis, and lymphoblastic leukemia.
• In-hospital universal screening, such as for hearing impairment, represents a new model for newborn diagnostics.

Findings:

• The expansion of newborn screening faces challenges, including the lack of preventive treatments for many potential disorders.
• Abnormal screening results may indicate susceptibility rather than a definitive diagnosis, complicating clinical management.
• Historical screening experiences, like those with histidinemia and alpha 1-antitrypsin deficiency, highlight the importance of evaluating medical benefit and psychological impact.

Implications:

• Future newborn screening will likely incorporate a wider range of metabolic and non-metabolic disorders using advanced technologies.
• Developing consensus and clear criteria for newborn screening inclusion is essential, involving key health organizations.
• Lessons learned from past screening endeavors are critical for ensuring responsible and effective future newborn screening strategies.